Current promising treatment strategy for glioblastoma multiform: A review.

IF 3.1 Q2 ONCOLOGY Oncology Reviews Pub Date : 2019-07-25 eCollection Date: 2019-07-22 DOI:10.4081/oncol.2019.417

Sanjib Bahadur, Arvind Kumar Sahu, Pragya Baghel, Suman Saha

{"title":"Current promising treatment strategy for glioblastoma multiform: A review.","authors":"Sanjib Bahadur, Arvind Kumar Sahu, Pragya Baghel, Suman Saha","doi":"10.4081/oncol.2019.417","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.</p>","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 2","pages":"417"},"PeriodicalIF":3.1000,"publicationDate":"2019-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/85/onco-13-2-417.PMC6661528.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2019.417","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/7/22 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Glioblastoma multiform (GBM) is a heterogeneous group of primary neoplasm resistant to conventional therapies. Due to their infiltrative nature it not fully isolated by aggressive surgery, radiation and chemotherapy showing poor prognosis in glioma patients. Unfortunately, diagnosed patients die within 1.5-2 year treatment schedule. Currently temozolomide (TMZ) is the first choice for the prognosis of GBM patients. TMZ metabolites methyl triazen imidazol carboxamide form complex with alkyl guanine alkyl transferase (O6 MGMT- DNA repair protein) induced DNA damage following resistance properties of TMZ and inhibit the overall survival of the patients. Last few decades different TMZ conjugated strategy is developed to overcome the resistance and enhance the chemotherapy efficacy. The main aim of this review is to introduce the new promising pharmaceutical candidates that significantly influence the therapeutic response of the TMZ in context of targeted therapy of glioblastoma patients. It is hoped that this proposed strategy are highly effective to overcome the current resistance limitations of TMZ in GBM patients and enhance the survival rate of the patients.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多形性胶质母细胞瘤目前有前景的治疗策略：综述。

多形性胶质母细胞瘤（GBM）是一组对传统治疗具有耐药性的异质性原发性肿瘤。由于其浸润性，在神经胶质瘤患者中，未通过积极的手术、放疗和化疗完全分离，显示预后不良。不幸的是，确诊患者在1.5-2年的治疗计划内死亡。目前替莫唑胺（TMZ）是GBM患者预后的首选药物。TMZ代谢产物甲基三氮杂咪唑甲酰胺与烷基鸟嘌呤烷基转移酶（O6-MGMT-DNA修复蛋白）形成复合物，诱导TMZ抗性后的DNA损伤，并抑制患者的总体生存。在过去的几十年里，人们开发了不同的TMZ结合策略来克服耐药性并提高化疗疗效。这篇综述的主要目的是介绍在胶质母细胞瘤患者的靶向治疗中显著影响TMZ治疗反应的新的有前景的候选药物。希望这一策略能非常有效地克服目前TMZ在GBM患者中的耐药性限制，提高患者的生存率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology Reviews ONCOLOGY-

CiteScore

6.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.